<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ep-patent-document PUBLIC "-//EPO//EP PATENT DOCUMENT 1.5//EN" "ep-patent-document-v1-5.dtd">
<ep-patent-document id="EP06759003B1" file="EP06759003NWB1.xml" lang="en" country="EP" doc-number="1912583" kind="B1" date-publ="20150107" status="n" dtd-version="ep-patent-document-v1-5">
<SDOBI lang="en"><B000><eptags><B001EP>......DE..ES..GB..IT................................................................................</B001EP><B003EP>*</B003EP><B005EP>J</B005EP><B007EP>JDIM360 Ver 1.28 (29 Oct 2014) -  2100000/0</B007EP></eptags></B000><B100><B110>1912583</B110><B120><B121>EUROPEAN PATENT SPECIFICATION</B121></B120><B130>B1</B130><B140><date>20150107</date></B140><B190>EP</B190></B100><B200><B210>06759003.4</B210><B220><date>20060504</date></B220><B240><B241><date>20071205</date></B241><B242><date>20091218</date></B242></B240><B250>en</B250><B251EP>en</B251EP><B260>en</B260></B200><B300><B310>678096 P</B310><B320><date>20050505</date></B320><B330><ctry>US</ctry></B330><B310>415782</B310><B320><date>20060205</date></B320><B330><ctry>US</ctry></B330></B300><B400><B405><date>20150107</date><bnum>201502</bnum></B405><B430><date>20080423</date><bnum>200817</bnum></B430><B450><date>20150107</date><bnum>201502</bnum></B450><B452EP><date>20140725</date></B452EP></B400><B500><B510EP><classification-ipcr sequence="1"><text>A61B  18/18        20060101AFI20061204BHEP        </text></classification-ipcr></B510EP><B540><B541>de</B541><B542>KOSMETISCHE LASERBEHANDLUNGSVORRICHTUNG FÜR LOKALISIERTE LIPODYSTROPHIEN UND SCHLAFFE HAUT</B542><B541>en</B541><B542>COSMETIC LASER TREATMENT DEVICE FOR LOCALIZED LIPODYSTROPHIES AND FLACCIDITY</B542><B541>fr</B541><B542>DISPOSITIF DE TRAITEMENT COSMETIQUE AU LASER POUR SUPPRESSION DE LIPODYSTROPHIES ET DE FLACCIDITE LOCALISEES</B542></B540><B560><B561><text>WO-A-00/09023</text></B561><B561><text>US-A- 5 102 410</text></B561><B561><text>US-A1- 2003 100 824</text></B561><B561><text>US-A1- 2004 059 397</text></B561><B561><text>US-B1- 6 206 873</text></B561><B561><text>US-B1- 6 206 873</text></B561><B561><text>US-B1- 6 254 597</text></B561><B561><text>US-B2- 6 605 079</text></B561><B565EP><date>20090911</date></B565EP></B560></B500><B700><B720><B721><snm>CASTRO, Danilo, Suarez, Dr.</snm><adr><str>26 de Marzo 10025</str><city>Montevideo, 11300</city><ctry>UY</ctry></adr></B721><B721><snm>NEUBERGER, Wolfgang</snm><adr><str>905 Beta Tower Financial Park</str><city>Labuan, 87000 F. T.</city><ctry>MY</ctry></adr></B721></B720><B730><B731><snm>Biolitec Pharma Marketing Ltd.</snm><iid>101312934</iid><irf>B15078EP</irf><adr><str>Level 6 (D) 
Main Office Tower 
Financial Park Labuan 
Jalan Merdeka 
87018 Labuan</str><city>F.T. Labuan</city><ctry>MY</ctry></adr></B731></B730><B740><B741><snm>Herrmann, Franz</snm><sfx>et al</sfx><iid>100954303</iid><adr><str>Dendorfer &amp; Herrmann 
Patentanwälte Partnerschaft 
Bayerstrasse 3</str><city>80335 München</city><ctry>DE</ctry></adr></B741></B740></B700><B800><B840><ctry>DE</ctry><ctry>ES</ctry><ctry>GB</ctry><ctry>IT</ctry></B840><B860><B861><dnum><anum>US2006017027</anum></dnum><date>20060504</date></B861><B862>en</B862></B860><B870><B871><dnum><pnum>WO2006121734</pnum></dnum><date>20061116</date><bnum>200646</bnum></B871></B870><B880><date>20080423</date><bnum>200817</bnum></B880></B800></SDOBI>
<description id="desc" lang="en"><!-- EPO <DP n="1"> -->
<heading id="h0001"><b>Background of the Invention</b></heading>
<p id="p0001" num="0001">1. <b>Domestic Priority under 35 USC 119(e).</b> This application claims the benefit of <patcit id="pcit0001" dnum="US67809605P" dnum-type="L"><text>U.S. Provisional Application Serial No. 60/678,096, filed May 5, 2005</text></patcit>.</p>
<heading id="h0002">2. <b>Field of the Invention</b></heading>
<p id="p0002" num="0002">The present invention relates to the field of cosmetic surgery and, in particular, relates to laser surgery to remove excess adipose cells in areas of the body prone to buildup of such tissues and further these areas are not amenable to long term removal of these tissues by exercise and/or diets.</p>
<heading id="h0003">3. <b>Invention Disclosure Statement</b></heading>
<p id="p0003" num="0003">It is a well known fact that modem society has created an abundance of readily available foods, i.e., "fast food," and also created an environment where entertainment has fostered a sedentary life style of, for example, watching television, playing video games and talking on the phone while eating high caloric snack foods. This has allowed people to gain excessive weight by an increase in adipose tissue, fat cells. Certain heredity conditions further have also created areas of excessive fat cells that are difficult to remove in that they are in areas that are not affected or minimally affected by diet and exercise.</p>
<p id="p0004" num="0004">Excessive fat depositions or "lipodystrophies" are produced by a disproportionate increase in the deeper section of the subcutaneous cellular tissues.</p>
<p id="p0005" num="0005">Lipodystrophies are produced because the adiposities have a hereditary genetic code which makes them evolve in a specific way. Each adipocite cell has Beta 1 (lipogenetic) and Alfa 2 (lipolitic) receptors in its membrane. When there are more Beta 1 receptors on a particular area, then a localized obesity or lipodystrophy is produced. Because of the excessive Beta receptors in certain families, these families have a tendency for enlarged legs, breasts, waists, etc. On these patients treatment with low caloric diets exclusively is normally not successful which leads to<!-- EPO <DP n="2"> --> abandonment of the treatment and recovering whatever localized fat was removed and returning to the same unhealthful practices.</p>
<p id="p0006" num="0006">The only effective way to treat lipodystrophies is to directly act on the genetically altered fat tissues and similar tissues in the area of treatment.</p>
<p id="p0007" num="0007">Historically, different methods have been developed to treat this problem and billions of dollars are being spent annually by people to remove or reduce fat,tissue. By the late 70's liposuction started to be used followed by liposculpture in the late 80's being an improved liposuction performed under local anesthesia using traumatic trocars to remove fluids. Later ultrasonic liposculpture was developed by mid 90's and there are some reports on "laser liposuction" (using an external laser source) which is not clearly proved to be effective so far.</p>
<p id="p0008" num="0008">Some patents of interest are:
<ul id="ul0001" list-style="none" compact="compact">
<li><patcit id="pcit0002" dnum="US5807385A"><text>U.S. Pat. No. 5,807,385 by Keller</text></patcit>, titled Method of Laser Cosmetic Surgery, discloses cosmetic laser surgery for eliminating wrinkles, frowns, and folds, for example. A quartz fiber is inserted into the skin and laser radiation in the range from 532 to 1060 nm is noted with a preferred wavelength of 532 nm. The use of various medical devices for removing wrinkles and other unwanted features such as hooks, retractors, bivalve speculum, etc., is noted.</li>
<li><patcit id="pcit0003" dnum="US6106516A"><text>U.S. Pat. No. 6,106,516 by Massengill</text></patcit>, titled, "Laser-Assisted Liposuction Method and Apparatus," discloses a liposuction cannula having a lumen from a source of water, a means for suction for removing the water, and a laser source within the cannula for heating the water in an active area of the tip of the cannula. The heated water leaves the tip and heats the surrounding fatty tissue to a point of liquefaction. The laser radiation does not directly affect any tissue.</li>
<li><patcit id="pcit0004" dnum="US6206873B"><text>U.S. Pat. No. 6,206,873 by Paolini, et al.</text></patcit>, titled, "Device and Method for Eliminating Adipose Layers by Means of Laser Energy," discloses a hollow needle with an optical fiber in the center. The fat tissues, adipose cells, are liquidized when the cell walls are broken. The fluid is removed by suction through the needle. Laser wavelength range is noted as from 0.75 to 2.5 microns but a preferred wavelength of 1.06 is called out. A rounded optical fiber end is shown in <figref idref="f0003">Fig. 3</figref> beyond the needle end. Paolini et al. use a Nd:YAG type of laser and note a wavelength range above. Paolini et al. further note that the liquid produced may be removed from the body by normal absorption, etc. Col. 4, lines 32 to 39.</li>
<li><patcit id="pcit0005" dnum="US6605080B"><text>U.S. Pat. No.6,605,080 by Altshuler et al.</text></patcit>, titled, "Method and Apparatus for the Selective Targeting of Lipid-Rich Tissues," discloses the removal of lipid rich tissue. The external laser, a<!-- EPO <DP n="3"> --> YAG source as well as other lasers, output energy with a wavelength range of 880 to 935 nm, 1150 to 1230 nm or 2280 to 2360. It notes that the radiation in the lower band, for example, 900 to 930, and 1150 to 1230, may be preferred in the treatment of fat tissue. Col. 11, line 55 to Col. 12, line 9. The laser light is applied externally and suction by cannula or hypodermic needle may be used to remove the lipid tissue that has been destroyed and formed into liquid. Col. 12, lines 30 to 55. Also, cooling to the skin tissue is noted. Col. 11, lines 1 to 22. The danger of using internal laser energy to remove fat tissue is noted on Col. 6, lines 50 to 64, because of the high power required.</li>
</ul></p>
<p id="p0009" num="0009">There is thus a need for a treatment technique that minimizes surface distortion, post operative complications, and removes adipose cells in selected areas. The present invention satisfies that need.</p>
<heading id="h0004"><b>Objectives and Brief Summary of the Invention</b></heading>
<p id="p0010" num="0010">It is an object of the present invention to provide a device for cosmetic surgery using laser radiation applied by an optical fiber to an area of treatment.</p>
<p id="p0011" num="0011">It is another object of the present invention to provide laser radiation for the destruction of fat tissue in the area of treatment.</p>
<p id="p0012" num="0012">It is a further object of the present invention to provide laser radiation of a wavelength of about 980 nm.</p>
<p id="p0013" num="0013">It is a still further object of the present invention to provide laser radiation that directly affects the fat tissues to destroy the targeted adiposities.</p>
<p id="p0014" num="0014">It is at least one aim of the present invention is to provide laser radiation from a high power source to quickly heat targeted tissue for destruction.</p>
<p id="p0015" num="0015">It is another aim of the present invention to provide laser radiation that directly affects the fat tissues especially in areas of the body resistant to diet and exercise.</p>
<p id="p0016" num="0016">It is also another aim of the present invention to provide laser radiation that directly affects the sub-dermal fatty tissues.</p>
<p id="p0017" num="0017">It is at least one goal of the present invention to provide laser radiation that directly affects adiposite causing emulsification of the fatty tissue and then elimination by absorption, removal by the lymphatic system and by drainage.<!-- EPO <DP n="4"> --></p>
<p id="p0018" num="0018">It is another goal of the present invention to provide laser radiation that directly affects the fat tissues without destruction of the structural tissues.</p>
<p id="p0019" num="0019">It is a further goal of the present invention to provide laser radiation that reduces skin flaccidity by up to 50% or more.</p>
<p id="p0020" num="0020">It is also a further goal of the present invention to provide laser radiation that directly affects cellulites resulting in strengthening and flatness to the skin affected by the laser treatment.</p>
<p id="p0021" num="0021">Briefly stated, the present invention provides a device for cosmetic surgery, especially fat reduction and collagen reformation, by means of a high power laser operating at about 980 nm. The cosmetic surgery method substantially reduces or removes localized lipodystrophies, and essentially reduces flaccidity by localized laser heating of adipose tissue using an optical fiber inserted into a treatment area. The method and device are particularly well suited for treating Lipodystrophies with flaccidity High power laser energy is applied to "fat" cells to breakdown the cell walls releasing the cell fluid. The laser radiation is applied through an optical fiber which may be held within a catheter-like device having a single lumen. The optical fiber may have a diffuser mounted on the tip to further apply heating to tissues surrounding the whole tip. A saline solution may also be inserted into the treatment site to aid in the heating of the fat cells and their eventual destruction as well as their removal. The pool of cell fluid in the area of treatment is removed by a combination of techniques including allowing the body to remove it by absorption and drainage from the entry sites thus minimizing trauma to the area of treatment and hastening recovery. Additional techniques to remove the cell fluid include direct force application by means of elastic bandages and external suction applied to the entry sites. Quick and lasting cosmetic changes, even in areas having prior untreatable fat tissues, are achieved while minimizing trauma to the treatment areas.</p>
<p id="p0022" num="0022">The above, and other objects, features and advantages of the present invention will become apparent from the following description read in conjunction with the accompanying drawings (in which like reference numbers in different drawings designate the same elements).</p>
<heading id="h0005"><b>Brief Description of the Drawings</b></heading><!-- EPO <DP n="5"> -->
<p id="p0023" num="0023">
<ul id="ul0002" list-style="none" compact="compact">
<li><figref idref="f0001">FIGS. 1A and 1B</figref> illustrate by photographs the before and after appearance of lower eyelids treated by the device of the present invention as an example of the effective treatment provided by the present invention.</li>
<li><figref idref="f0002">FIG. 2</figref> illustrate, by schematic devices of the present invention.</li>
<li><figref idref="f0003">FIGS. 3A and 3B</figref> illustrate, by a cross sectional elevational view, two different embodiments of the needle like device of the present invention.</li>
<li><figref idref="f0004">FIG. 4</figref> illustrates, by a cross sectional elevational view, an optical fiber in a cannula for the present invention.</li>
<li><figref idref="f0005">FIGS. 5A and 5B</figref> illustrate by photographs the before and after appearance of the dorsal area treated by the device of the present invention as an example of the effective treatment provided by the present invention.</li>
<li><figref idref="f0005">FIGS. 6A and 6B</figref> illustrate by photographs the before and after appearance of the external side of the thigh treated by the device of the present invention as an example of the effective treatment provided by the present invention.</li>
<li><figref idref="f0006 f0007">FIGS. 7A to 7F</figref> illustrate different devices for the application of laser radiation and the removal of liquid from the area of treatment.</li>
</ul></p>
<heading id="h0006"><b>Detailed Description of the Preferred Embodiments</b></heading>
<p id="p0024" num="0024">The invention is defined in the appended set of claims.</p>
<p id="p0025" num="0025">The present invention describes a device for cosmetic surgery by means of a high power laser operating at about 980 nm. The cosmetic surgery method substantially reduces or removes localized lipodystrophies and/or flaccidity by localized heating of adipose tissue by means of an optical fiber inserted into an area of treatment. The high power laser energy is applied to heat the "fat" cells to a temperature wherein the cell walls break releasing the cell fluid. The laser radiation is applied by an optical fiber and the optical fiber may be held within a catheter-like device having a single lumen therein. The optical fiber may have a diffuser mounted on the tip to facilitate heating tissues surrounding the whole tip. To further aid in heating of the fat cells, a saline solution is infused into the treatment site. The pool of cell fluid in the area of treatment may be removed by a combination of techniques including allowing the body to eliminate it by absorption and/or removal, drainage from the entry sites thus minimizing trauma to the area of treatment, direct force application by means of elastic bandages and external suction applied to the<!-- EPO <DP n="6"> --> entry sites. The devices of the present invention provide for quick and lasting cosmetic changes in areas having prior untreatable fat tissues while at the same time minimizing trauma to the areas of treatment.</p>
<p id="p0026" num="0026">In one embodiment the technique uses a 15w - 980 nm diode laser to rid the patient of aesthetically unpleasing fat and reduce flaccidity on different parts of the body, especially in areas that are resistant to change by dieting and exercising.</p>
<p id="p0027" num="0027">The treatment with the 980 nm laser proved to be efficient and more suitable rather than traditional liposuction on up to 80% of the patients. Each adiposite has a fat content which is emulsified by the laser action and then absorbed and eliminated via lymphatic system. Lipids are formed by a Glycerol chain and 3 units of 3-fatty acids. Heat dissociates the lipids and glycerol is expelled by urine. 3-fatty acids as energy units are easily used by the body and as other polyunsaturated oils are eliminated via lymphatic (which can take a few weeks) and hepatic systems. In contrast with liposuction and its modifications, this method preserves the structural tissues, acting only on the fat cells. Furthermore, it generates a fibro-elastic retraction which can reduce skin flaccidity by up to 50%. This later effect is produced by a partial denaturisation of the extra cellular matrix. The treatment also acts on the fibrotic tracts typical of cellulites returning the strength and flatness to the skin.</p>
<p id="p0028" num="0028">The procedures followed in the present invention are as follows: The area of treatment is marked to differentiate by depth and approximate volume (cm<sup>3</sup>) of excess adipose tissues. The area of treatment is (sterilized) disinfected. The insertion sites are marked. The patient is placed on sterile surrounding and local anesthesia is applied to the skin where there are going to be insertion sites. A small entry is made and the site is widened and pre-tunneled into the subcutaneous tissue by using a small, curved hemostat. A blunt infusion catheter is then inserted via this tunnel into the site, and tumescent anesthetic is delivered first to the deepest layer in a radial fashion and then successively more superficially. Infiltration of the anesthetic is then achieved by pump. A needle is selected according to the fiber diameter and inserted (e.g., 18G French for 600 um fibers on large areas and 25G French with a 220um fiber for face treatments) and a sterile optical fiber is then inserted. The appropriate treatment mode and the parameters of the laser are selected, e.g., as in Table 1. The position of the fiber tip is controlled by the laser aiming beam. The pre-selected energy is applied and the fiber is moved to treat the desired area. Ultrasound guidance can be used to position the tip of the fiber. After all of the entry sites are treated, ultrasound and lymphatic<!-- EPO <DP n="7"> --> drainage post-procedures are followed. Elastic bandage is placed on the treated area for 3 to 5 days.</p>
<p id="p0029" num="0029">This treatment (in contrast with liposuction) preserves the structural tissues and elasticity of the skin with the addition of localized retraction and firming of the area. This reduces flaccidity by up to 50%.</p>
<p id="p0030" num="0030">In general after the first 72 hours of treatment, there is a considerable edema requiring ultrasound detection and lymphatic drainage. During the first 2 weeks, edema is reduced by around 80% and skin retraction appears. From 2 to 5 weeks, lymphatic edema disappears as well as the delimitation of the treated area. As a general observation, tissues on the treated area appeared more compacted with less irregularity on the surface and better elasticity, and the body shape improves continually and no additional changes are noted after about 40 to 60 days following the procedure.</p>
<p id="p0031" num="0031">Low power 980 nm laser is used to treat areas with cellulites. Results are permanent because the adiposite cells are destroyed. Only in very rare exceptions, these cells are reproduced as a side effect: after the laser application, a softening of the treated area appeared to the tact and harder limiting section on the limits of the treated area. This generates a lymphatic edema produced by the body to eliminate the emulsified fat after the procedure.</p>
<p id="p0032" num="0032">As to the success of the present invention, <figref idref="f0001"><b>FIGS. 1A</b> to <b>1B</b></figref> disclose pictures before and after of the interior eyelids; <figref idref="f0005"><b>FIGS. 5A</b> and <b>5B</b></figref> disclose pictures before and after of a thorax area; and <figref idref="f0005"><b>FIGS. 6A</b> and <b>6B</b></figref> disclose before and after pictures of the thigh and buttock area.</p>
<p id="p0033" num="0033"><figref idref="f0002"><b>FIG. 2</b></figref> shows laser radiation device <b><u>100</u></b> having optical fiber cable <b>102</b> connected into needle-like device <b>104</b> that is for insertion into treatment area <b>106.</b> Fluid pump <b>108</b> is used for inputting any fluids including the tumescent anesthetic fluid and the saline solution through line <b>114</b> into and through the needle like device <b>104.</b> After treatment, a fluid suction pump <b>116</b> having one or more hoses <b>110</b> with one or more suction heads <b>112</b> is placed on the entry sites to assist in the removal of liquid from the area of treatment.</p>
<p id="p0034" num="0034">As to needle like device <b>104,</b> several embodiments are shown in <figref idref="f0003">FIGS. <b>3A</b> and <b>3B</b></figref> as needles <b><u>300</u></b> and <b><u>302</u></b>. The entry ends are appropriately finished. As seen in <figref idref="f0003"><b>FIG. 3A</b></figref><b>,</b> needle <b><u>300</u></b> being in cross section has a plurality of optical fibers <b>304</b> circumferentially located about central lumen <b>306</b> which may be used for inputting fluids and for suction removal of fluids. Wall <b>308</b> surrounding fibers <b>304</b> may act as a cladding and whole needle <b><u>300</u></b> may be manufactured from a single preform of a material appropriately formed. <figref idref="f0003"><b>FIG. 3B</b></figref> illustrates by cross section another<!-- EPO <DP n="8"> --> needle like device <b><u>302</u></b> wherein a lumen <b>310</b> is centrally located in optical fiber <b>312</b> being a core fiber without any cladding shown. Appropriate cladding layer(s), buffer layer(s), and protective layer(s), although not shown, are understood to be present as needed.</p>
<p id="p0035" num="0035"><figref idref="f0004"><b>FIG. 4</b></figref> further illustrates another embodiment of a needle like device <b><u>400</u></b> wherein cannula wall <b>402</b> has central lumen <b>404</b> therein. Tip area <b>406</b> is appropriately formed as a slanted wedge. Inside of lumen <b>404</b> is attached either separately or integrally formed optical fiber <b>408</b>. Tip area <b>410</b> of optical fiber <b>406</b> is formed to have slanted output end <b>420</b> with mirror <b>412</b> formed thereon to cause optical radiation <b>414</b> to be output in a sidewise manner as shown between rays <b>416</b> and <b>418.</b> Mirror <b>412</b> formed on tip <b>420</b> need not have a surface congruent with the surface of tip <b>406</b> of cannula wall <b>402.</b> Alternatively, instead of adding mirror <b>412,</b> end is angled at the critical angle for reflection and the light exits fiber <b>406</b> perpendicularly to the fiber axis. Due to the closeness of the adipose tissue to the skin surface, a catheter or similar device may not be needed to guide the needle to area of treatment <b>106,</b> shown in <figref idref="f0002"><b>FIG. 2</b></figref><b>.</b> That is only the entering needle is needed to introduce the optical fiber to the fatty area to be treated.</p>
<p id="p0036" num="0036"><figref idref="f0006 f0007"><b>FIGS. 7A to 7F</b></figref> illustrate various devices for applying radiation, inputting fluids and removing fluids from an area of treatment within the body. The device <b><u>700A</u></b> comprises a cannula <b>702</b> with an end <b>704</b> fitted with an applicator tip <b>706A</b>. Cannula <b>700</b> has one or more lumens for holding one or more laser optical fibers <b>708</b> with a side-fire tip 710. An elongated aperture <b>712</b> is located along the traverse axis of application tip <b>706A.</b> Side-fire tip <b>710</b> is positioned within lumen <b>714</b> so as to allow the radiation output from side-fire tip <b>710</b> to exit through aperture <b>712.</b> The length of aperture <b>712</b> is several times the width of aperture <b>712</b> so as to allow a sufficient space for outputting and inputting fluid therethrough.</p>
<p id="p0037" num="0037">In <figref idref="f0006"><b>FIG. 7B</b></figref><b>,</b> applicator tip <b>706</b> has a first aperture <b>716</b> for radiation output from side-fire tip <b>710</b> and a second aperture <b>718</b> for inputting and removing fluids. Further, there may be multiple apertures <b>718</b> on applicator tip <b>706B</b> and further there may be separate apertures for inputting fluid and removing fluid appropriately located about tip <b>706.</b></p>
<p id="p0038" num="0038">In <figref idref="f0006"><b>FIG. 7C</b></figref><b>,</b> applicator tip <b>706C</b> has one aperture <b>720</b> for the control of fluids. Located about aperture <b>702</b> are a plurality of optical fiber outputs <b>722.</b></p>
<p id="p0039" num="0039">In <figref idref="f0007"><b>FIG. 7D</b></figref><b>,</b> applicator tip <b>706D</b> is attached to cannula end 704. An optical fiber <b>724</b> is placed within one lumen of cannula <b>702</b> and has an output tip <b>726</b> that directly communicates with applicator tip <b>706D.</b> Applicator tip <b>706D</b> is made from high quality optical silica, for example, and<!-- EPO <DP n="9"> --> has a reflective coating <b>728</b> positioned on a portion of the front end <b>730</b> so as to intercept output radiation from optical fiber <b>724</b> and reflect such in a radial direction as shown. Further application tip <b>706D</b> may include at least one lumen <b>732</b> therein that communicates with one lumen <b>734</b> in cannula <b>702.</b></p>
<p id="p0040" num="0040"><figref idref="f0007"><b>FIG. 7E</b></figref> discloses another embodiment where applicator tip <b>700E</b> has two laser output apertures <b>738</b> and <b>740</b> and two fluid control apertures <b>742</b> and <b>744.</b> Although this shows these located on the same side of the tip <b>700E,</b> other locations are equally feasible, for example, having the output apertures located on the opposite of the tip <b>700E.</b> Further, additional apertures may be included about the tip so as to reduce or eliminate the need for rotating the cannula <b>702</b> when outputting radiation and/or controlling fluid.</p>
<p id="p0041" num="0041"><figref idref="f0007"><b>FIG. 7F</b></figref> discloses another embodiment of applicator tip <b>700F</b> where optical fiber <b>724</b> has a wedge shaped termination <b>746</b> to spread the radiation from a front end <b>748.</b> One or more fluid control apertures <b>750</b> are included in applicator tip <b>700E.</b></p>
<p id="p0042" num="0042">The present invention is further illustrated by the following examples, but is not limited thereby. Table 1 illustrates the various parameters used in operating the diode laser of the present invention to remove excess adipose tissues in the areas noted:
<tables id="tabl0001" num="0001">
<table frame="all">
<title><b>Table 1</b></title>
<tgroup cols="5">
<colspec colnum="1" colname="col1" colwidth="29mm"/>
<colspec colnum="2" colname="col2" colwidth="21mm"/>
<colspec colnum="3" colname="col3" colwidth="20mm"/>
<colspec colnum="4" colname="col4" colwidth="29mm"/>
<colspec colnum="5" colname="col5" colwidth="25mm"/>
<thead>
<row>
<entry valign="top"/>
<entry align="center" valign="top"><b>Power [W]</b></entry>
<entry align="center" valign="top"><b>Time [sec]</b></entry>
<entry align="center" valign="top"><b>Energy [Joules]</b></entry>
<entry align="center" valign="top"><b>Nr. Of pulses</b></entry></row></thead>
<tbody>
<row>
<entry><b>Lower eyelids</b></entry>
<entry align="center">4 watts</entry>
<entry align="center">2 sec</entry>
<entry align="center">8 J</entry>
<entry align="center">20-30</entry></row>
<row>
<entry><b>Facial</b></entry>
<entry align="center">6 watts</entry>
<entry align="center">3 sec</entry>
<entry align="center">18 J</entry>
<entry align="center">40-70</entry></row>
<row>
<entry><b>Collar</b></entry>
<entry align="center">7 watts</entry>
<entry align="center">3 sec</entry>
<entry align="center">21 J</entry>
<entry align="center">40-70</entry></row>
<row>
<entry><b>Thorax</b></entry>
<entry align="center">12 watts</entry>
<entry align="center">3 sec</entry>
<entry align="center">36 J</entry>
<entry align="center">70 +</entry></row>
<row>
<entry><b>Abdomen</b></entry>
<entry align="center">15 watts</entry>
<entry align="center">2 sec</entry>
<entry align="center">30 J</entry>
<entry align="center">70 +</entry></row>
<row>
<entry><b>Thigh &amp; buttock</b></entry>
<entry align="center">12 watts</entry>
<entry align="center">3 sec</entry>
<entry align="center">16 J</entry>
<entry align="center">70 +</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0043" num="0043">Furthermore, this treatment is an out-patient alternative, minimally invasive, more elegant and with less risks and complications than current treatments. Although there is no need for hospitalization, it must be followed by a diet and physical ultrasound and lymphatic drainage. Results can be appreciated from about week 3 and final results achieved between weeks 6 and 10.<!-- EPO <DP n="10"> --></p>
<heading id="h0007">EXAMPLE 1</heading>
<p id="p0044" num="0044"><figref idref="f0001"><b>FIGS. 1A</b> and <b>1B</b></figref> illustrate by photographs the before and after appearance of lower eyelids treated by the device of the present invention as example of effective treatment of the present invention.</p>
<p id="p0045" num="0045">The laser energy is delivered through a disposable fiber optic directly into the sub-dermal tissue. This tissue is composed of adiposities and structural tissues irrigated by small arteries, veins and lymphatic. In the lower eyelids, the laser is pulsed 20 to 30 times at a power of 4 W delivering 8 Joules at 2 seconds per pulse.</p>
<p id="p0046" num="0046">The radiation of the Biolitec® 980 nm laser is selectively absorbed by the sub-dermal tissue which is surrounded by saline solution. By thermal effect (980 nm radiation is highly absorbed by water) the adipose membranes are destroyed. For example, using 15 watts for 3 seconds (45 Joules) the temperature reached on the tip of the fiber is around 100°C which is transmitted by the tumescent anesthesia diffusing and reducing the temperature to 70°C ± 10°C. It is thus considered that a minimum temperature of 50°C must be present to denature the cells' proteins and preferably the temperature of the cells being treated is in the range of 70°C ± 10°C. Moving the laser fiber back and forth, a 2 cm penetration with fat tissues dissociation is achieved.</p>
<heading id="h0008">EXAMPLE 2</heading>
<p id="p0047" num="0047"><figref idref="f0005"><b>FIGS. 5A</b> and <b>5B</b></figref> illustrate by photographs the before and after appearance of the dorsal area treated by the device of the present invention as an example of effective treatment of the present invention.</p>
<p id="p0048" num="0048">The laser energy is delivered through a disposable fiber optic directly into the sub-dermal tissue. This tissue is composed by adiposities and structural tissues irrigated by small arteries, veins and lymphatic. In the thorax area, the laser is pulsed more than 70 times at a power of 12 watts, 36 Joules at 3 seconds per pulse.</p>
<p id="p0049" num="0049">The radiation of the Biolitec® 980 nm laser is selectively absorbed by the sub-dermal tissue which is surrounded by saline solution. By thermal effect (980 nm radiation is highly absorbed by water) the adiposities membranes are destroyed. For example, using 15 watts for 3 seconds (45 Joules) the temperature reached on the tip of the fiber is around 100°C which is transmitted by the tumescent anesthesia diffusing and reducing to 70°C ± 10°C the temperature. It is thus considered that a minimum temperature of 50°C should be present to denature the cells' proteins and<!-- EPO <DP n="11"> --> preferably the temperature of the cells being treated is in the range of 70°C ± 10°C. Moving the laser fiber back and forth, a 2 cm penetration with fat tissues dissociation is achieved.</p>
<heading id="h0009">EXAMPLE 3</heading>
<p id="p0050" num="0050"><figref idref="f0005"><b>FIGS. 6A</b> and <b>6B</b></figref> illustrate by photographs the before and after appearance of the external side of the thigh treated by the device of the present invention as an example of effective treatment of the present invention.</p>
<p id="p0051" num="0051">The laser energy is delivered through a disposable fiber optic directly into the sub-dermal tissue. This tissue is composed by adiposities and structural tissues irrigated by small arteries, veins and lymphatic. In the thigh and buttock area, the laser is pulsed at least 70 times at a power of 15 watts, 30 Joules at 2 seconds per pulse</p>
<p id="p0052" num="0052">The radiation of the Biolitec® 980 nm laser is selectively absorbed by the sub-dermal tissue which is surrounded by saline solution. By thermal effect (980 nm radiation is highly absorbed by water) the adiposities membranes are destroyed. For example, using 15 watts for 3 seconds (45 Joules) the temperature reached on the tip of the fiber is around 100°C which is transmitted by the tumescent anesthesia diffusing and reducing the temperature to 70°C ± 10°C. It is thus considered that a minimum temperature of 50°C should be present to denature the cells' proteins and preferably the temperature of the cells being treated is in the range of 75°C ± 25°C. Moving the laser fiber back and forth, a 2 cm penetration with fat tissues dissociation is achieved.</p>
</description>
<claims id="claims01" lang="en"><!-- EPO <DP n="12"> -->
<claim id="c-en-01-0001" num="0001">
<claim-text>A treatment set for improving cosmetic appearance of a subject, comprising:
<claim-text>a diode laser configured to emit light having a wavelength of 980 nm for heating an adipose tissue to a temperature in the range of 75°C ± 25°C for reducing localized lipodystrophies and flaccidity with simultaneous collagen reformation;</claim-text>
<claim-text>an optical fiber (102, 308, 408, 708, 724) configured to deliver the light to a treatment site (106);</claim-text>
<claim-text>a cannula (104, 300, 402, 702) configured to introduce said optical fiber (308, 408, 708) to the treatment site (106); wherein said cannula (104, 300, 402, 702) has a lumen (306, 404, 734) for inputting a fluid into the treatment site and for outputting a fluid from the treatment site; and</claim-text>
<claim-text>a pump (108) for inputting the fluid through the lumen of the cannula (104, 300, 402, 702).</claim-text></claim-text></claim>
<claim id="c-en-01-0002" num="0002">
<claim-text>The treatment set according to claim 1,<br/>
wherein the cannula (104, 300, 402, 702) is formed by a cannula of a needle-like device (104, 300, 402).</claim-text></claim>
<claim id="c-en-01-0003" num="0003">
<claim-text>The treatment set according to claim 2,<br/>
wherein the tip of the fiber is anyled and configured to emit the light in a sidewise manner through the lateral surface (402) of the needle-like device (104, 300, 402).</claim-text></claim>
<claim id="c-en-01-0004" num="0004">
<claim-text>The treatment set according to claim 2,<br/>
wherein the needle-like device (104, 300, 402) has a front-side opening (406) for inputting a fluid into the treatment site (106) along a longitudinal direction of the needle-like device.</claim-text></claim>
<claim id="c-en-01-0005" num="0005">
<claim-text>The treatment set according to claim 1,<br/>
wherein the cannula (104, 702) has at least one lateral aperture (714, 718, 720, 732, 742, 744, 750) for inputting a fluid into the treatment site (106) and for removing a fluid therefrom.<!-- EPO <DP n="13"> --></claim-text></claim>
<claim id="c-en-01-0006" num="0006">
<claim-text>The treatment set according to claim 1,<br/>
wherein the cannula (104, 702) has at least one lateral aperture (714, 716, 722, 738, 740) for transmitting the light in a radial direction towards the treatment site (106).</claim-text></claim>
<claim id="c-en-01-0007" num="0007">
<claim-text>The treatment set according to claim 6,<br/>
wherein the cannula (104, 702) has at least one further lateral aperture (718, 720, 732, 742, 744) for inputting a fluid into the treatment site (106).</claim-text></claim>
<claim id="c-en-01-0008" num="0008">
<claim-text>The treatment set according to claim 6,<br/>
wherein the cannula has a further lateral aperture (720) for inputting a fluid into the treatment site, and wherein the at least one lateral aperture for transmitting the light comprises multiple lateral apertures (722) for transmitting the light arranged around said further lateral aperture (720) for inputting a fluid into the treatment site (106).</claim-text></claim>
<claim id="c-en-01-0009" num="0009">
<claim-text>The treatment set according to claim 6,<br/>
wherein the at least one lateral aperture for transmitting the light consists of a lateral aperture (714) for transmitting the light which is furthermore configured to input a fluid into the treatment site (106).</claim-text></claim>
<claim id="c-en-01-0010" num="0010">
<claim-text>The treatment set according to claim 6,<br/>
wherein the cannula tip (706B) features first apertures (718) for inputting fluid into the treatment site and separate second apertures for removing fluid from the treatment site (106).</claim-text></claim>
<claim id="c-en-01-0011" num="0011">
<claim-text>The treatment set according to claim 1 to 10,<br/>
wherein the optical fiber is a side-firing fiber (408, 708).</claim-text></claim>
<claim id="c-en-01-0012" num="0012">
<claim-text>The treatment set according to claim 11,<br/>
comprising a reflector (412, 728) configured to reflect light delivered through the optical fiber (408, 708) in a radial direction towards the treatment site (106).</claim-text></claim>
<claim id="c-en-01-0013" num="0013">
<claim-text>The treatment set according to claim 1,<br/>
<!-- EPO <DP n="14"> -->wherein the optical fiber (724) has a wedge-shaped tip (746) configured to spread the light from the front end of the cannula (702).</claim-text></claim>
<claim id="c-en-01-0014" num="0014">
<claim-text>The treatment set according to claim 1,<br/>
wherein said diode laser is a high power laser having an output of about 15 W, or wherein said diode laser delivers energy from about 5 joules to about 30 joules.</claim-text></claim>
<claim id="c-en-01-0015" num="0015">
<claim-text>The treatment set according to claim 1,<br/>
wherein said optical fiber has a diameter from about 200 µm to about 1000 µm,<br/>
preferably wherein the cannula is a 18 gauge needle or 25 gauge needle, wherein the optical fiber is about a 600 µm optical fiber or about a 200 µm optical fiber, and wherein the 18 gauge needle is selected for the 600 µm optical fiber, and the 25 gauge needle for the 200 µm optical fiber.</claim-text></claim>
</claims>
<claims id="claims02" lang="de"><!-- EPO <DP n="15"> -->
<claim id="c-de-01-0001" num="0001">
<claim-text>Behandlungsset für die Verbesserung der kosmetischen Erscheinung eines Subjekts mit:
<claim-text>einem Diodenlaser, der dazu eingerichtet ist, Licht mit einer Wellenlänge von 980 nm zu emittieren, um fetthaltiges Gewebe zum Verringern lokalisierter Lipodystrophien und schlaffer Haut mit gleichzeitiger Kollagenneubildung auf eine Temperatur im Bereich von 75°C ± 25°C zu erwärmen;</claim-text>
<claim-text>einer optischen Faser (102, 308, 408, 708, 724), die dazu eingerichtet ist, einem Behandlungsort (106) Licht zuzuführen;</claim-text>
<claim-text>einer Kanüle (104, 300, 402, 702), die dazu eingerichtet ist, die optische Faser (308, 408, 708) zum Behandlungsort (106) einzuführen, wobei die Kanüle (104, 300, 402, 702) ein Lumen (306, 404, 734) zum Einführen eines Fluids zum Behandlungsort und zum Abführen eines Fluids vom Behandlungsort aufweist; und</claim-text>
<claim-text>einer Pumpe (108), um das Fluid durch das Lumen der Kanüle (104, 300, 402, 702) zuzuführen.</claim-text></claim-text></claim>
<claim id="c-de-01-0002" num="0002">
<claim-text>Behandlungsset nach Anspruch 1,<br/>
bei dem die Kanüle (104, 300, 402, 702) durch eine Kanüle eines nadelartigen Geräts (104, 300, 402) gebildet ist.</claim-text></claim>
<claim id="c-de-01-0003" num="0003">
<claim-text>Behandlungsset nach Anspruch 2,<br/>
bei dem die Spitze der Faser im Winkel angeordnet ist und dazu eingerichtet ist, Licht seitlich durch die seitliche Oberfläche (402) des nadelartigen Geräts (104, 300, 402) zu emittieren.</claim-text></claim>
<claim id="c-de-01-0004" num="0004">
<claim-text>Behandlungsset nach Anspruch 2,<br/>
bei dem das nadelartige Gerät (104, 300, 402) eine vorderseitige Öffnung (406) aufweist, um dem Behandlungsort (106) Fluid entlang der Längsrichtung des nadelartigen Geräts zuzuführen.<!-- EPO <DP n="16"> --></claim-text></claim>
<claim id="c-de-01-0005" num="0005">
<claim-text>Behandlungsset nach Anspruch 1,<br/>
bei dem die Kanüle (104, 702) wenigstens eine seitliche Öffnung (714, 718, 720, 732, 742, 744, 750) aufweist, um dem Behandlungsort (106) ein Fluid zuzuführen und um Fluid von dort abzuführen.</claim-text></claim>
<claim id="c-de-01-0006" num="0006">
<claim-text>Behandlungsset nach Anspruch 1,<br/>
bei dem die Kanüle (104, 702) wenigstens eine seitliche Öffnung (714, 716, 722, 738, 740) zur Übertragung des Lichts in eine radiale Richtung zum Behandlungsort (106) aufweist.</claim-text></claim>
<claim id="c-de-01-0007" num="0007">
<claim-text>Behandlungsset nach Anspruch 6,<br/>
bei dem die Kanüle (104, 702) wenigstens eine weitere seitliche Öffnung (718, 720, 732, 742, 744) aufweist, um einem Behandlungsort (106) Fluid zuzuführen.</claim-text></claim>
<claim id="c-de-01-0008" num="0008">
<claim-text>Behandlungsset nach Anspruch 6,<br/>
bei dem die Kanüle eine weitere seitliche Öffnung (720) für die Zufuhr von Fluid zum Behandlungsort aufweist, und bei dem die wenigstens eine seitliche Öffnung zur Übertragung von Licht mehrfache seitliche Öffnungen (722) zur Übertragung von Licht aufweist, die um die weitere seitliche Öffnung (720) für die Zufuhr von Fluid zum Behandlungsort (106) angeordnet sind.</claim-text></claim>
<claim id="c-de-01-0009" num="0009">
<claim-text>Behandlungsset nach Anspruch 6,<br/>
bei dem die wenigstens eine seitliche Öffnung zur Übertragung von Licht aus einer seitlichen Öffnung (714) zur Übertragung von Licht besteht, die ferner dazu eingerichtet ist, ein Fluid dem Behandlungsort (106) zuzuführen.</claim-text></claim>
<claim id="c-de-01-0010" num="0010">
<claim-text>Behandlungsset nach Anspruch 6,<br/>
bei dem die Kanülenspitze (706B) erste Öffnungen (718) aufweist, um Fluid dem Behandlungsort zuzuführen, und getrennte zweite Öffnungen, um Fluid vom Behandlungsort (106) abzuführen.<!-- EPO <DP n="17"> --></claim-text></claim>
<claim id="c-de-01-0011" num="0011">
<claim-text>Behandlungsset nach Anspruch 1 bis 10,<br/>
bei dem die optische Faser eine seitlich abstrahlende Faser (408, 708) ist.</claim-text></claim>
<claim id="c-de-01-0012" num="0012">
<claim-text>Behandlungsset nach Anspruch 11,<br/>
das einen Reflektor (412, 728) aufweist, der dazu eingerichtet ist, durch die optische Faser (408, 708) zugeführtes Licht in radiale Richtung zum Behandlungsort (106) zu reflektieren.</claim-text></claim>
<claim id="c-de-01-0013" num="0013">
<claim-text>Behandlungsset nach Anspruch 1,<br/>
bei dem die optische Faser (724) eine keilförmige Spitze (746) aufweist, die dazu eingerichtet ist, das Licht vom vorderen Ende der Kanüle (702) zu verteilen.</claim-text></claim>
<claim id="c-de-01-0014" num="0014">
<claim-text>Behandlungsset nach Anspruch 1,<br/>
bei dem der Diodenlaser ein Hochleistungslaser mit einer Ausgangsleistung von etwa 15 W ist oder bei dem der Diodenlaser Energie von etwa 5 Joule bis etwa 30 Joule liefert.</claim-text></claim>
<claim id="c-de-01-0015" num="0015">
<claim-text>Behandlungsset nach Anspruch 1,<br/>
bei dem die optische Faser einen Durchmesser von etwa 200 zum bis ungefähr 1000 µm hat, wobei die Kanüle vorzugsweise eine Nadel der Größe 18 oder eine Nadel der Größe 25 ist und die optische Faser eine ungefähr 600 µm optische Faser oder eine ungefähr 200 µm optische Faser ist und die Nadeln der Größe 18 für die 600 µm optische Faser und die Nadeln der Größe 25 für die 200 µm optische Faser ausgewählt sind.</claim-text></claim>
</claims>
<claims id="claims03" lang="fr"><!-- EPO <DP n="18"> -->
<claim id="c-fr-01-0001" num="0001">
<claim-text>Un kit de traitement destiné à l'amélioration d'un aspect cosmétique d'un sujet, comprenant :
<claim-text>un laser à diode configuré de façon à émettre une lumière possédant une longueur d'onde de 980 nm pour le chauffage d'un tissu adipeux à une température dans la plage de 75°C ± 25°C pour la réduction d'une flaccidité et de lipodystrophies localisées avec reformation simultanée de collagène,</claim-text>
<claim-text>une fibre optique (102, 308, 408, 708, 724) configurée de façon à fournir de la lumière à un site de traitement (106),</claim-text>
<claim-text>une canule (104, 300, 402, 702) configurée de façon à introduire ladite fibre optique (308, 408, 708) dans le site de traitement (106), ladite canule (104, 300, 402, 702) possédant un lumen (306, 404, 734) destiné à l'introduction d'un fluide dans le site de traitement et à la production en sortie d'un fluide à partir du site de traitement, et</claim-text>
<claim-text>une pompe (108) destinée à l'introduction du fluide par l'intermédiaire du lumen de la canule (104, 300, 402, 702).</claim-text></claim-text></claim>
<claim id="c-fr-01-0002" num="0002">
<claim-text>Le kit de traitement selon la Revendication 1,<br/>
dans lequel la canule (104, 300, 402, 702) est formée par une canule d'un dispositif de type aiguille (104, 300, 402).</claim-text></claim>
<claim id="c-fr-01-0003" num="0003">
<claim-text>Le kit de traitement selon la Revendication 2,<br/>
dans lequel la pointe de la fibre est oblique et<br/>
est configurée de façon à émettre la lumière de manière latérale au travers de la surface latérale (402) du dispositif de type aiguille (104, 300, 402).<!-- EPO <DP n="19"> --></claim-text></claim>
<claim id="c-fr-01-0004" num="0004">
<claim-text>Le kit de traitement selon la Revendication 2,<br/>
dans lequel le dispositif de type aiguille (104, 300, 402) possède une ouverture côté avant (406) destinée à l'introduction d'un fluide dans le site de traitement (106) le long d'une direction longitudinale du dispositif de type aiguille.</claim-text></claim>
<claim id="c-fr-01-0005" num="0005">
<claim-text>Le kit de traitement selon la Revendication 1,<br/>
dans lequel la canule (104, 702) possède au moins une ouverture latérale (714, 718, 720, 732, 742, 744, 750) destinée à l'introduction d'un fluide dans le site de traitement (106) et au retrait d'un fluide de celui-ci.</claim-text></claim>
<claim id="c-fr-01-0006" num="0006">
<claim-text>Le kit de traitement selon la Revendication 1,<br/>
dans lequel la canule (104, 702) possède au moins une ouverture latérale (714, 716, 722, 738, 740) pour la transmission de la lumière dans une direction radiale vers le site de traitement (106).</claim-text></claim>
<claim id="c-fr-01-0007" num="0007">
<claim-text>Le kit de traitement selon la Revendication 6,<br/>
dans lequel la canule (104, 702) possède au moins une autre ouverture latérale (718, 720, 732, 742, 744) destinée à l'introduction d'un fluide dans le site de traitement (106).</claim-text></claim>
<claim id="c-fr-01-0008" num="0008">
<claim-text>Le kit de traitement selon la Revendication 6,<br/>
dans lequel la canule possède une autre ouverture latérale (720) destinée à l'introduction d'un fluide dans le site de traitement, et dans lequel la au moins une ouverture latérale pour la transmission de la lumière comprend une pluralité d'ouvertures latérales (722) pour la transmission de la lumière agencées autour de ladite autre ouverture<!-- EPO <DP n="20"> --> latérale (720) destinée à l'introduction d'un fluide dans le site de traitement (106).</claim-text></claim>
<claim id="c-fr-01-0009" num="0009">
<claim-text>Le kit de traitement selon la Revendication 6,<br/>
dans lequel la au moins une ouverture latérale pour la transmission de la lumière se compose d'une ouverture latérale (714) pour la transmission de la lumière qui est en outre configurée de façon à introduire un fluide dans le site de traitement (106).</claim-text></claim>
<claim id="c-fr-01-0010" num="0010">
<claim-text>Le kit de traitement selon la Revendication 6,<br/>
dans lequel la pointe de la canule (706B) comprend des premières ouvertures (718) destinées à l'introduction d'un fluide dans le site de traitement et des deuxièmes ouvertures distinctes destinées au retrait d'un fluide du site de traitement (106).</claim-text></claim>
<claim id="c-fr-01-0011" num="0011">
<claim-text>Le kit de traitement selon les Revendications 1 à 10,<br/>
dans lequel la fibre optique est une fibre à tir latéral (408, 708).</claim-text></claim>
<claim id="c-fr-01-0012" num="0012">
<claim-text>Le kit de traitement selon la Revendication 11,<br/>
comprenant un réflecteur (412, 728) configuré de façon à réfléchir une lumière fournie par l'intermédiaire de la fibre optique (408, 708) dans une direction radiale vers le site de traitement (106).</claim-text></claim>
<claim id="c-fr-01-0013" num="0013">
<claim-text>Le kit de traitement selon la Revendication 1,<br/>
dans lequel la fibre optique (724) possède une pointe en biseau (746) configurée de façon à diffuser la lumière provenant de l'extrémité avant de la canule (702).<!-- EPO <DP n="21"> --></claim-text></claim>
<claim id="c-fr-01-0014" num="0014">
<claim-text>Le kit de traitement selon la Revendication 1,<br/>
dans lequel ledit laser à diode est un laser haute puissance possédant une sortie d'environ 15 W, ou dans lequel ledit laser à diode fournit une énergie d'environ 5 joules à environ 30 joules.</claim-text></claim>
<claim id="c-fr-01-0015" num="0015">
<claim-text>Le kit de traitement selon la Revendication 1,<br/>
dans lequel ladite fibre optique possède un diamètre d'environ 200 µm à environ 1000 µm, de préférence dans lequel la canule est une aiguille de calibre 18 ou une aiguille de calibre 25, dans lequel la fibre optique est une fibre optique d'environ 600 µm ou une fibre optique d'environ 200 µm, et dans lequel l'aiguille de calibre 18 est sélectionnée pour la fibre optique d'environ 600 µm et l'aiguille de calibre 25 pour la fibre optique d'environ 200 µm.</claim-text></claim>
</claims>
<drawings id="draw" lang="en"><!-- EPO <DP n="22"> -->
<figure id="f0001" num="1A,1B"><img id="if0001" file="imgf0001.tif" wi="136" he="230" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="23"> -->
<figure id="f0002" num="2"><img id="if0002" file="imgf0002.tif" wi="157" he="126" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="24"> -->
<figure id="f0003" num="3A,3B"><img id="if0003" file="imgf0003.tif" wi="149" he="194" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="25"> -->
<figure id="f0004" num="4"><img id="if0004" file="imgf0004.tif" wi="165" he="163" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="26"> -->
<figure id="f0005" num="5A,5B,6A,6B"><img id="if0005" file="imgf0005.tif" wi="150" he="231" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="27"> -->
<figure id="f0006" num="7A,7B,7C"><img id="if0006" file="imgf0006.tif" wi="165" he="214" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="28"> -->
<figure id="f0007" num="7D,7E,7F"><img id="if0007" file="imgf0007.tif" wi="165" he="223" img-content="drawing" img-format="tif"/></figure>
</drawings>
<ep-reference-list id="ref-list">
<heading id="ref-h0001"><b>REFERENCES CITED IN THE DESCRIPTION</b></heading>
<p id="ref-p0001" num=""><i>This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.</i></p>
<heading id="ref-h0002"><b>Patent documents cited in the description</b></heading>
<p id="ref-p0002" num="">
<ul id="ref-ul0001" list-style="bullet">
<li><patcit id="ref-pcit0001" dnum="US67809605P" dnum-type="L"><document-id><country>US</country><doc-number>67809605</doc-number><kind>P</kind><date>20050505</date></document-id></patcit><crossref idref="pcit0001">[0001]</crossref></li>
<li><patcit id="ref-pcit0002" dnum="US5807385A"><document-id><country>US</country><doc-number>5807385</doc-number><kind>A</kind><name>Keller</name></document-id></patcit><crossref idref="pcit0002">[0008]</crossref></li>
<li><patcit id="ref-pcit0003" dnum="US6106516A"><document-id><country>US</country><doc-number>6106516</doc-number><kind>A</kind><name>Massengill</name></document-id></patcit><crossref idref="pcit0003">[0008]</crossref></li>
<li><patcit id="ref-pcit0004" dnum="US6206873B"><document-id><country>US</country><doc-number>6206873</doc-number><kind>B</kind><name>Paolini</name></document-id></patcit><crossref idref="pcit0004">[0008]</crossref></li>
<li><patcit id="ref-pcit0005" dnum="US6605080B"><document-id><country>US</country><doc-number>6605080</doc-number><kind>B</kind><name>Altshuler </name></document-id></patcit><crossref idref="pcit0005">[0008]</crossref></li>
</ul></p>
</ep-reference-list>
</ep-patent-document>
